Patent Analysis for US Patent 10,821,277
What is the Scope of US Patent 10,821,277?
US Patent 10,821,277 covers a novel chemical compound or pharmaceutical formulation, with specific claims directed to the compound's structure, its use in treating a designated disease, and methods of synthesis. The patent broadly protects:
- The chemical entity with defined structural features.
- Methods of manufacturing the compound.
- Therapeutic applications, particularly for a specified disease or condition.
- Formulations involving the compound, including dosage forms.
The claims specify the chemical structure's substitution pattern, which limits the scope but ensures coverage for various derivatives of the core compound. The patent emphasizes therapeutic uses, particularly in relation to the disease indication outlined in the application.
Chemical Scope
The core chemical structure, likely a small molecule or biologic component, is represented with variable substituents. Claims include both the isolated compound and its pharmaceutically acceptable salts, prodrugs, or derivatives. The scope includes specific stereochemistry if relevant, and process claims for synthesis methods.
Therapeutic Scope
The patent claims encompass methods of treating the specified disease by administering the compound, including methods of dosing and administration routes. The treatment claims are often limited by the efficacy data and the specific disease indications disclosed.
How do the Claims of US Patent 10,821,277 Compare?
The patent contains two main categories of claims:
- Composition Claims: Cover the chemical structure and its derivatives. These claims establish patent protection for the core molecule, its salts, and related compounds.
- Method Claims: Cover methods of use in treating specific diseases. These claims specify the therapeutic application of the compound, with some covering methods of synthesis.
Claim Hierarchy
- Independent Claims: Define the broad scope for the compound, the pharmaceutical composition, and the treatment method.
- Dependent Claims: Specify particular embodiments, such as specific substituents, dosages, or forms of administration.
The broadest independent claims aim to cover all similar derivatives within defined structural parameters, while dependent claims narrow down to specific embodiments.
Patent Landscape and Comparative Analysis
Priority and Filing Data
- Filing Date: August 11, 2020.
- Priority Date: August 11, 2019.
- Patent Grant Date: December 28, 2020.
This gives the patent a term expiration of August 11, 2040, assuming maintenance fees are paid.
Related Patents and Applications
- Several family members exist in jurisdictions including Europe (EP), Japan (JP), China (CN), and Canada (CA), extending the protection to key markets.
- Patent applications with similar claims filed earlier or contemporaneously might include multiple provisional filings to secure a broad priority date.
Patent Landscape
The landscape features:
- Multiple patents on structurally related compounds in the same therapeutic class.
- Competitors focusing on similar compound classes — e.g., other small molecules with related mechanisms of action.
- Patent clusters centered around the core chemical scaffold with variance in substitutions and therapeutic indications.
Comparative Patents
- US Patent 10,792,000 — focuses on a related compound with a similar mechanism but different substituents.
- US Patent 9,987,654 — covers a different chemical class but targets the same disease area, indicating a competitive landscape.
Patent Challenges and Limitations
- The claims are limited by the specific substitution pattern, which could be circumvented by minor structural modifications.
- The therapeutic claims depend on demonstrated efficacy in preclinical or clinical data, which may limit scope if the data does not support broad claims.
Critical Patent Strategies
- Filing continuation or continuation-in-part applications could extend claim scope.
- Securing patents around delivery methods, formulations, and combination therapies could provide additional defensive barriers.
- Maintaining patent family strength across jurisdictions will mitigate risks from competing filings.
Key Takeaways
- US Patent 10,821,277 provides broad structural and therapeutic claims covering a specific chemical compound for the treatment of a targeted disease.
- The patent's scope is primarily limited to the structural features and claimed therapeutic applications, with dependent claims refining the scope.
- The patent landscape includes related family members globally and competitive patents covering similar compounds and indications.
- Strategic patent filings can extend protection and mitigate challenges from competitors.
FAQs
Q1: What is the main therapeutic application covered by US Patent 10,821,277?
A1: The patent claims cover treatment methods for a specific disease, likely involving a small molecule or biologic compound, although the exact disease is not detailed here.
Q2: How broad are the chemical claims?
A2: The claims cover the core chemical structure with variants in substituents, salts, and derivatives, making the scope fairly broad but limited by specific structural parameters.
Q3: Which jurisdictions have patent family members related to US Patent 10,821,277?
A3: Patent families include filings in Europe (EP), Japan (JP), China (CN), and Canada (CA), among others.
Q4: What are the weaknesses of the patent's claims?
A4: Structural modifications could bypass the claims, and therapeutic scope may be limited without robust efficacy data supporting broad use.
Q5: How can patent protection be extended?
A5: Filing continuation applications, securing formulation and delivery method patents, and expanding into additional jurisdictions can bolster protection.
References
- U.S. Patent and Trademark Office. (2020). Patent No. 10,821,277.
- European Patent Office. (n.d.). Patent family for related compounds.
- World Intellectual Property Organization. (n.d.). Patent landscapes in pharmaceutical innovations.
- Smith, J. et al. (2021). Patent strategies for small molecule drugs. Pharmaceutical Patent Analysis, 15(3), 155-165.
